Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
Canada
· Delayed Price · Currency is CAD 10.91
+0.11 (1.02%)
At close: Mar 6, 2026
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 33 employees as of December 31, 2024. The number of employees increased by 4 or 13.79% compared to the previous year.
Employees
33
Change (1Y)
4
Growth (1Y)
13.79%
Revenue / Employee
n/a
Profits / Employee
-1.34M CAD
Market Cap
655.97M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Bright Minds Biosciences | 26 |
| Satellos Bioscience | 17 |
| Helix BioPharma | 7 |
| Medicenna Therapeutics | 18 |
| Sernova Biotherapeutics | 8 |
Eupraxia Pharmaceuticals News
- 15 days ago - Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option - GlobeNewsWire
- 16 days ago - Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants - GlobeNewsWire
- 17 days ago - Eupraxia Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy - GlobeNewsWire
- 4 months ago - Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI - GlobeNewsWire
- 4 months ago - Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs - GlobeNewsWire
- 5 months ago - Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option - GlobeNewsWire